Suppr超能文献

一种用于宫颈癌筛查的新型 HPV 自我采样设备的验证:Cervical and Self-Sample In Screening(CASSIS)研究。

Validation of a new HPV self-sampling device for cervical cancer screening: The Cervical and Self-Sample In Screening (CASSIS) study.

机构信息

Division of Cancer Epidemiology, McGill University, Montreal, Canada.

Gynecologic Cancer Service, McGill University Health Centre - Glen Site Cedars Cancer Centre, Montreal, Canada.

出版信息

Gynecol Oncol. 2018 Jun;149(3):491-497. doi: 10.1016/j.ygyno.2018.04.004. Epub 2018 Apr 17.

Abstract

OBJECTIVE

We compared the self-sampling performance of the newly designed HerSwab™ device with a physician-collected cervical sample and another self-sample using the cobas® PCR Female swab for the detection of cervical intraepithelial neoplasia (CIN) and cancer.

METHODS

Women referred for colposcopy at McGill University affiliated hospital clinics collected two consecutive self-samples, one with HerSwab™ and one with cobas® swab, after receiving instructions. The order of sampling was randomized. The colposcopist then collected a cervical sample and conducted a colposcopic examination. Samples were tested for human papillomavirus (HPV) DNA. Sensitivity and specificity to detect CIN2+ and respective 95% confidence intervals (CI) were calculated to compare sampling approaches. The HPV testing agreement between samples was measured using the Kappa statistic.

RESULTS

Of 1217 women enrolled, 1076 had complete results for HPV and cytology; 148 (13.8%) had CIN1, 147 (13.7%) had CIN2/3, and 5 (0.5%) had cancer. There was very good agreement between methods for HPV detection (HerSwab™ versus physician: kappa=0.84; cobas® swabs versus physician: kappa=0.81; HerSwab™ versus cobas® swabs: kappa=0.87). The sensitivity of HPV detection for CIN2+ was 87.6% (95%CI: 79.8-93.2) with self-sampling using HerSwab™, 88.6% (95%CI: 80.9-94.0) with self-sampling using the cobas® swab, and 92.4% (95%CI: 85.5-96.7) with physician sampling. Corresponding estimates of specificity were 58.1% (95%CI: 54.1-62.1), 55.0% (95%CI: 50.9-59.0) and 58.7% (95%CI: 54.6-62.6). Cytology (ASC-US or more severe) done on the physician-collected specimen was 80.2% (95%CI: 70.8-87.6) sensitive and 61.4% (95%CI: 57.2-65.5) specific for CIN2+.

CONCLUSIONS

The HerSwab™ had good agreement with physician sampling in detecting HPV, and adequate performance in detecting high-grade lesions among women referred to colposcopy for abnormal cytology.

摘要

目的

我们比较了新设计的 HerSwab™ 装置与医生采集的宫颈样本以及另一种使用 cobas® PCR 女性拭子进行的自我采样,以检测宫颈上皮内瘤变(CIN)和癌症。

方法

在麦吉尔大学附属医院诊所就诊的女性在接受指导后,连续采集两次自我样本,一次使用 HerSwab™,一次使用 cobas®拭子。采样顺序随机。然后,阴道镜医生采集宫颈样本并进行阴道镜检查。对样本进行人乳头瘤病毒(HPV)DNA 检测。计算检测 CIN2+的敏感性和特异性,并计算各自的 95%置信区间(CI),以比较采样方法。使用 Kappa 统计量测量样本之间 HPV 检测的一致性。

结果

在 1217 名入组女性中,1076 名女性的 HPV 和细胞学检测结果完整;148 名(13.8%)患有 CIN1,147 名(13.7%)患有 CIN2/3,5 名(0.5%)患有癌症。HPV 检测方法之间具有很好的一致性(HerSwab™ 与医生:kappa=0.84; cobas®拭子与医生:kappa=0.81; HerSwab™ 与 cobas®拭子:kappa=0.87)。使用 HerSwab™ 进行自我采样时,HPV 检测对 CIN2+的敏感性为 87.6%(95%CI:79.8-93.2),使用 cobas®拭子进行自我采样时为 88.6%(95%CI:80.9-94.0),医生采样时为 92.4%(95%CI:85.5-96.7)。相应的特异性估计值分别为 58.1%(95%CI:54.1-62.1)、55.0%(95%CI:50.9-59.0)和 58.7%(95%CI:54.6-62.6)。医生采集的标本进行细胞学(ASC-US 或更严重)检测时,对 CIN2+的敏感性为 80.2%(95%CI:70.8-87.6),特异性为 61.4%(95%CI:57.2-65.5)。

结论

HerSwab™ 在检测 HPV 方面与医生采样具有良好的一致性,在对细胞学异常的女性进行阴道镜检查时,对高级别病变的检测性能足够。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验